MSB 3.06% $1.01 mesoblast limited

Sorry thought I answered this - my reply seems not to have gone...

  1. 2,072 Posts.
    lightbulb Created with Sketch. 1185
    Sorry thought I answered this - my reply seems not to have gone through.

    The FDA is key performance indicated against the number of BLAs and BLA resubmissions it manages to do in a a period of a year or so - it has to report on those. This means it has to project manage so as to give itself the best chance to achieve a 6 month response time once it has accepted a resubmission for review.

    Booking and sending inspectors to Singapore would be something necessary to do unless it was already clear the BLA resubmission was going to fail. Presupposing failure - before taking a good look at all the details of the submission would be wrong - so booking and doing an inspection is just necessary to try to ensure the FDA can give a response in 6 months as its supposed to do.

    Reviewing all the info in BLA resubmission critically and fairly is a big project - it has to be handled with critical path analysis for the FDA to meet its time commitments - that why in my opinion.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.01
Change
0.030(3.06%)
Mkt cap ! $1.153B
Open High Low Value Volume
$1.01 $1.04 99.0¢ $5.111M 5.050M

Buyers (Bids)

No. Vol. Price($)
2 211966 $1.01
 

Sellers (Offers)

Price($) Vol. No.
$1.02 136540 9
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.